Spector, Roseman, & Kodroff, P.C. Announces Class Periods for Securities Class Action Lawsuits Against Accelr8 Technology Corp., Citrix Systems, Inc., S1 Corp., PE Corp. Celera Genomics Group, Cyber-Care, Inc., First Security Corp., Flooring America, Inc

Business Wire, June 22, 2000

Business Editors/Legal Writers

PHILADELPHIA--(BUSINESS WIRE)--June 22, 2000

SPECTOR, ROSEMAN, & KODROFF has filed Class Action lawsuits against or asked to investigate the following companies at the request of shareholders who purchased securities during the Class Periods stated below. Investors who purchased any of the following securities during the stated Class Periods are invited to contact us to learn more about these lawsuits. If you wish to discuss these actions or have any questions concerning this notice or your rights or interests, please contact plaintiffs' counsel Robert M. Roseman toll-free at 1-888-844-5862 or via E-mail at classaction@spectorandroseman.com.

ACCELR8 TECHNOLOGY CORP. (NASDAQ: ACLY) 9/15/97 - 11/16/99: This action arises out of a series of materially false and misleading statements Defendants allegedly made concerning the business and financial operations of Accelr8. Specifically, Defendants materially overstated the Company's revenue, improperly recognized revenue relating to licensing and maintenance fees, and failed to amortize capitalized software and development costs. Moreover, according to the complaint, the Company failed to disclose that Accelr8's Navig8 2000 software, created to fix the millennium bug, was in fact only available to a computer system manufactured by Digital Equipment Corp. ("DEC"), and was not available as a general Year 2000 remediation tool for all of the programs that would need Year 2000 solutions, contrary to the Company's repeated assertions during the Class Period. When these accounting violations came to light, the Company's auditors, Deloitte & Touche LLP, informed the Company that their audit report, dated September 15, 1998, on the Company's financial statements for the years ended July 31, 1997 and 1998 should no longer be relied upon, and resigned as Accelr8's auditors. The Complaint alleges, amongst other things, that, as a result of these material misstatements and omissions, the Company's stock price was artificially inflated throughout the Class Period.

CITRIX SYSTEMS, INC. (NASDAQ: CTXS) 10/18/99 - 6/9/00: The complaint alleges that the defendants issued materially false and misleading information concerning, among other things, the Company's financial and operating condition and the Company's prospects. Specifically, during the Class Period, defendants issued a series of public statements touting the Company's "record" financial results. After numerous repeated public announcements emphasizing the Company's success, Citrix stock soared to over $181 per share on February 10, 2000, and traded at well over $100 a share in March, 2000, after a two-for-one stock split on February 17, 2000. On June 12, 2000, Citrix took investors and analysts by surprise, announcing that the company's financial results for the second quarter of fiscal 2000 would be far from what investors had been led to believe due to, among other things, poor overall sales attributable to a market shift towards an electronic delivery of programs and upgrades, and particularly poor sales in its Asian market. In response, the price of Citrix common stock fell over 40% to $22 per share - - a far cry from the pre-split Class Period high of nearly $182 per share.

S1 CORP. (Nasdaq: SONE) 11/2/99 - 5/2/00: The complaint charges S1 and certain of its directors and executive officers with violations of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint alleges that the defendants issued false and misleading information concerning, among other things, S1's ability to integrate two companies that S1 acquired in November, 1999. As a result of S1's false and misleading statements, the price of the stock was artificially inflated during the class period.

PE CORP. CELERA GENOMICS GROUP (NYSE: CRA) 2/29/00: The Class consists of all persons who purchased the stock of PE Corporation Celera Genomics Group in a secondary offering (the "Secondary Offering") of Celera common stock conducted by PE Corporation on February 29, 2000. The complaint charges Celera and certain of its officers and directors with violating Sections 11, 12(a)(2) and 15(a) of the Securities Act of 1933. The complaint alleges that the registration statement and prospectus issued in conjunction with the Secondary Offering were materially false and misleading in that they failed to disclose that Celera had engaged in discussions with the Human Genome Project (an international research organization supported by the U.S. and U.K. governments, among others) concerning collaborating on completing the map of the human genome and that those discussions had terminated in December 1999 because the Human Genome Project was opposed to Celera's demands for five-year exclusive rights to the data.

CYBER-CARE, INC. (Nasdaq: CYBR) 11/3/99 - 5/12/00: The complaint alleges that the defendants made false and misleading statements regarding the successful sales of its Internet-based Electronic Housecall System ("EHC"), causing the stock to reach a class period high of over $37 per share. In May 2000, it was revealed that the U.S. Food and Drug Administration was investigating Cyber-Care for violating federal rules prohibiting the sale and restricting the marketing of non-FDA approved products. Additionally, many of the "customers" that defendants represented as entering into contracts for the purchase of EHC units did not have anywhere near the financial stability to enter into multi-million dollar contracts.